Research programme: anti-angiogenesis peptides - Affymax/EntreMed
Latest Information Update: 27 Aug 2009
At a glance
- Originator Affymax; EntreMed
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors; VLDL receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2008 Preclinical development is ongoing in USA
- 16 Jan 2006 Preclinical trials in Cancer in USA (unspecified route)